Targeting Oxidative Stress Could Fill a Gap in the Vitiligo Treatment Toolbox

For the estimated up to 2% of the global population living with vitiligo, achieving stable repigmentation has remained one of dermatology's most persistent clinical challenges. Emerging molecular evidence suggests that correcting oxidative imbalance may be a critical missing piece.¹

Vitiligo, Autoimmunity, and the Burden of Chronic Skin Disease

Vitiligo is a chronic acquired autoimmune disorder in which melanocytes—the pigment-producing cells of the skin—are progressively destroyed, resulting in well-demarcated white patches that can appear on any body surface, including the face, hands, hair, and genital region. The condition affects individuals equally across all age groups, sexes, skin types, and ethnicities. People with vitiligo also carried an elevated risk of comorbid autoimmune conditions, including thyroid disease, alopecia areata, and diabetes, sharing a predominant Th1-based immune pattern.

Despite the established use of topical corticosteroids and calcineurin inhibitors and the more recent introduction of Janus kinase (JAK) inhibitors—which interrupted the IFN-γ signaling pathway—stable, long-term repigmentation remained difficult to achieve. A more complete understanding of disease pathogenesis was needed to advance treatment.

Oxidative Stress as an Upstream Trigger: Molecular Evidence

A review published in Biomtypolecules examined how chronic oxidative disequilibrium initiates and sustains the autoimmune cascade in vitiligo.¹ The authors, affiliated with Hospital Vito Fazzi in Lecce and the San Gallicano Dermatological Institute in Rome, analyzed molecular and clinical evidence across multiple studies and population cohorts.

Prior scholarship had already begun to clarify the molecular basis for this investigative focus. A 2023 review in Cells found that melanin synthesis—a process unique to melanocytes—acts as a significant endogenous ROS source, rendering pigment-producing cells constitutively vulnerable to oxidative injury.² Under normal physiological conditions, the Nrf2 pathway provides a primary cellular defense against oxidative stress by upregulating antioxidant and detoxification gene expression; however, when antioxidant defenses are deficient or chronic inflammation disrupts redox balance, ROS accumulate and cause molecular and cellular damage. The authors further noted that excessive ROS drove surface exposure of melanocyte-specific autoantigens, activating both innate and adaptive immune responses and driving melanocyte cytotoxicity—a cascade consistent with the mechanistic framework examined by the Aprile et al. review. The findings reinforced growing consensus that oxidative stress and autoimmunity in vitiligo were not independent events but deeply intertwined processes requiring integrated therapeutic strategies.

People with vitiligo demonstrated significantly increased hydrogen peroxide levels in skin lesions alongside markedly reduced activity of key antioxidant enzymes, including catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPX), and glutathione S-transferase (GST).¹ Red blood cell analyses showed that SOD activity and malondialdehyde (MDA) levels were significantly elevated and positively correlated with disease extent and activity, while CAT and glucose-6-phosphate dehydrogenase (G6PD) activities were significantly reduced—findings the authors described as supporting the hypothesis that widespread enzymatic deficiencies underpin vitiligo pathogenesis.

At the cellular level, ROS accumulation drove mitochondrial dysfunction, endoplasmic reticulum stress-mediated unfolded protein response (UPR) activation, and peroxisomal defects—collectively generating proinflammatory cytokines and chemokines that recruited cytotoxic T lymphocytes and accelerated melanocyte loss. Genetic polymorphisms in antioxidant enzyme genes were associated with elevated disease susceptibility across Korean, Chinese, Italian, Turkish, and Saudi populations.

Antioxidant Interventions: Combination Therapy Drove Meaningful Outcomes

The review assessed a broad range of antioxidant agents evaluated in clinical trials. Antioxidant monotherapy produced limited repigmentation benefit. However, several agents showed meaningful synergy when combined with phototherapy or standard pharmacological regimens.

Vitamins C and E enhanced outcomes when paired with narrowband UVB (NB-UVB) or topical corticosteroids, particularly in younger individuals or those with recent disease onset. Alpha-lipoic acid and polyunsaturated fatty acids demonstrated repigmentation enhancement in combination with NB-UVB or betamethasone. Plant-derived compounds—including Ginkgo biloba, Polypodium leucotomos, and curcumin—showed antioxidant and immunomodulatory activity. While Ginkgo biloba was the only plant-derived compound to show monotherapy efficacy in arresting depigmentation, the authors cautioned that clinical evidence for phytomedicines in vitiligo remains limited.

Emerging regenerative strategies, including adipose-derived stem cells and platelet-rich plasma, were noted for their capacity to neutralize ROS and support melanocyte viability. However, the review cautioned that the intrinsic oxidative burden documented in vitiligo may limit the utility of autologous materials.

Limitations: Conflicting Data and the Absence of Standardized Biomarkers

The review identified several important limitations in the existing evidence base. Published data on oxidant and antioxidant levels in people with vitiligo were conflicting across studies, with some groups reporting elevated blood SOD activity while others described reductions. Differences in genetic background and environmental factors were proposed as contributing factors.

Critically, no standardized oxidative biomarkers currently existed to reliably monitor disease activity or therapeutic response—a gap the authors flagged as a major barrier to personalized clinical management. Clinical evidence for plant-derived compounds also remained limited in scope and rigor, and most clinical trials involving platelet-rich plasma had not investigated oxidative mechanisms specifically.

"A significant gap remains the lack of standardized oxidative biomarkers to monitor disease activity and therapeutic response," the authors wrote. "Identifying these indicators is essential for personalized clinical management in vitiligo."

Future Directions: Targeted Combination Strategies Represent Viable Path Forward

The review authors concluded that targeting oxidative stress—whether as adjunctive therapy or alongside JAK inhibitor-based regimens—represented a clinically relevant and underutilized treatment axis. They called for larger, more rigorous trials for cell-based therapies and phytomedicines to establish the safety and efficacy profiles necessary for broader clinical adoption, while emphasizing that no single antioxidant approach was likely to be sufficient on its own.

References

1. Aprile N, Scano S, Bellei B, Marini A, Filoni A. Targeting oxidative stress to treat vitiligo: clinical and molecular evidence. Biomolecules. 2026;16(4):612. doi:10.3390/biom16040612
2. Chang WL, Ko CH. The role of oxidative stress in vitiligo: an update on its pathogenesis and therapeutic implications. Cells. 2023;12(6):936. doi:10.3390/cells12060936.